{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:49:08Z","timestamp":1791244148163,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01308-5","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:02:02Z","timestamp":1768212122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9512-0253","authenticated-orcid":false,"given":"Majd","family":"Al Assaad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5156-9086","authenticated-orcid":false,"given":"Max F.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9428-4125","authenticated-orcid":false,"given":"Daniela","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6608-5778","authenticated-orcid":false,"given":"Marvel","family":"Tranquille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5358-8414","authenticated-orcid":false,"given":"Abigail","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Otilano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunes","family":"Gundem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Medina-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0328-8359","authenticated-orcid":false,"given":"Michael","family":"Sigouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Manohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-7105","authenticated-orcid":false,"given":"Hui-Hsuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-1145","authenticated-orcid":false,"given":"David C.","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Andreopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Chapman-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-8587","authenticated-orcid":false,"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6915-3070","authenticated-orcid":false,"given":"Andrea","family":"Sboner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson J.","family":"Ocean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-9655","authenticated-orcid":false,"given":"Manish A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-2627","authenticated-orcid":false,"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-9617","authenticated-orcid":false,"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4666-6476","authenticated-orcid":false,"given":"Juan Miguel","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"1308_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart, M. D. et al. Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27, 167\u2013174 (2022).","journal-title":"Oncologist"},{"key":"1308_CR2","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","volume":"31","author":"RE Miller","year":"2020","unstructured":"Miller, R. E. et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann. Oncol. 31, 1606\u20131622 (2020).","journal-title":"Ann. Oncol."},{"key":"1308_CR3","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen, L., W. M. Martens, J., Van Hoeck, A. & Cuppen, E. Pan-cancer landscape of homologous recombination deficiency. Nat. Commun. 11, 5584 (2020).","journal-title":"Nat. Commun."},{"key":"1308_CR4","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/bcr3655","volume":"16","author":"MA Vollebergh","year":"2014","unstructured":"Vollebergh, M. A. et al. Genomic patterns resembling BRCA-and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 16, R47 (2014).","journal-title":"Breast Cancer Res."},{"key":"1308_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","volume":"108","author":"A Dr\u00e9an","year":"2016","unstructured":"Dr\u00e9an, A., Christopher, J. L. & Alan, A. PARP inhibitor combination therapy. Crit. Rev. Oncol. Hematol. 108, 73\u201385 (2016).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1308_CR6","doi-asserted-by":"publisher","unstructured":"Chai, Y. et al. Homologous Recombination Deficiency (HRD) and BRCA 1\/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): a systematic review and meta-analysis. J. Pers. Med. 12 https:\/\/doi.org\/10.3390\/jpm12020323 (2022).","DOI":"10.3390\/jpm12020323"},{"key":"1308_CR7","doi-asserted-by":"publisher","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","volume":"5","author":"I Pokataev","year":"2020","unstructured":"Pokataev, I. et al. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 5, e000578 (2020).","journal-title":"ESMO Open"},{"key":"1308_CR8","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta, M., George, A., Kaye, S. B. & Banerjee, S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann. Oncol. 27, 1449\u20131455 (2016).","journal-title":"Ann. Oncol."},{"key":"1308_CR9","first-page":"862","volume":"23","author":"U Varol","year":"2018","unstructured":"Varol, U. et al. BRCA genes: BRCA 1 and BRCA 2. J. Buon 23, 862\u2013866 (2018).","journal-title":"J. Buon"},{"key":"1308_CR10","first-page":"81","volume":"809","author":"JH Seol","year":"2018","unstructured":"Seol, J. H., Shim, E. Y. & Lee, S. E. Microhomology-mediated end joining: good, bad and ugly. Mutat. Res. 809, 81\u201387 (2018).","journal-title":"Mutat. Res."},{"key":"1308_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-025-00740-y","volume":"13","author":"A Witz","year":"2025","unstructured":"Witz, A. et al. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics. Biomark. Res. 13, 31 (2025).","journal-title":"Biomark. Res."},{"key":"1308_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13059-019-1867-0","volume":"20","author":"\u00c1 P\u00f3ti","year":"2019","unstructured":"P\u00f3ti, \u00c1 et al. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biol. 20, 240 (2019).","journal-title":"Genome Biol."},{"key":"1308_CR13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"1308_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.gde.2021.01.002","volume":"66","author":"J Setton","year":"2021","unstructured":"Setton, J., Reis-Filho, J. S. & Powell, S. N. Homologous recombination deficiency: how genomic signatures are generated. Curr. Opin. Genet Dev. 66, 93\u2013100 (2021).","journal-title":"Curr. Opin. Genet Dev."},{"key":"1308_CR15","doi-asserted-by":"publisher","unstructured":"Akinjiyan, F. A. et al. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms241310771 (2023).","DOI":"10.3390\/ijms241310771"},{"key":"1308_CR16","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1308_CR17","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman, R. L. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 381, 2403\u20132415 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1308_CR18","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury, C. A. et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 17, e0264138 (2022).","journal-title":"PLoS One"},{"key":"1308_CR19","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","volume":"14","author":"P Ter Brugge","year":"2023","unstructured":"Ter Brugge, P. et al. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers. Nat. Commun. 14, 1958 (2023).","journal-title":"Nat. Commun."},{"key":"1308_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116\u20131120 (2008).","journal-title":"Nature"},{"key":"1308_CR21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111\u20131115 (2008).","journal-title":"Nature"},{"key":"1308_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","volume":"10","author":"SJ Pettitt","year":"2020","unstructured":"Pettitt, S. J. et al. Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 10, 1475\u20131488 (2020).","journal-title":"Cancer Discov."},{"key":"1308_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi, R. et al. Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518, 258\u2013262 (2015).","journal-title":"Nature"},{"key":"1308_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13058-022-01572-6","volume":"24","author":"E Ballot","year":"2022","unstructured":"Ballot, E. et al. Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive\/HER2-negative early breast cancers. Breast Cancer Res. 24, 80 (2022).","journal-title":"Breast Cancer Res."},{"key":"1308_CR25","doi-asserted-by":"publisher","unstructured":"Kekeeva, T. et al. Molecular subgroups of HRD positive ovarian cancer and their prognostic significance. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms252413549 (2024).","DOI":"10.3390\/ijms252413549"},{"key":"1308_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525 (2017).","journal-title":"Nat. Med."},{"key":"1308_CR27","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra, N. et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 11, 2662 (2020).","journal-title":"Nat. Commun."},{"key":"1308_CR28","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.annonc.2021.08.2154","volume":"32","author":"D Hodgson","year":"2021","unstructured":"Hodgson, D. et al. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann. Oncol. 32, 1582\u20131589 (2021).","journal-title":"Ann. Oncol."},{"key":"1308_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-020-0172-0","volume":"6","author":"XM de Luca","year":"2020","unstructured":"de Luca, X. M. et al. Using whole-genome sequencing data to derive the homologous recombination deficiency scores. npj Breast Cancer 6, 33 (2020).","journal-title":"npj Breast Cancer"},{"key":"1308_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12864-018-5096-9","volume":"19","author":"S Bruinsma","year":"2018","unstructured":"Bruinsma, S. et al. Bead-linked transposomes enable a normalization-free workflow for NGS library preparation. BMC Genomics 19, 722 (2018).","journal-title":"BMC Genomics"},{"key":"1308_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1200\/JCO.2023.41.6_suppl.225","volume":"41","author":"JT Nauseef","year":"2023","unstructured":"Nauseef, J. T. et al. Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers. J. Clin. Oncol. 41, 225\u2013225 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1308_CR32","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41467-022-30233-7","volume":"13","author":"N Shukla","year":"2022","unstructured":"Shukla, N. et al. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nat. Commun. 13, 2485 (2022).","journal-title":"Nat. Commun."},{"key":"1308_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12859-020-03879-7","volume":"21","author":"JS Medina-Mart\u00ednez","year":"2020","unstructured":"Medina-Mart\u00ednez, J. S. et al. Isabl Platform, a digital biobank for processing multimodal patient data. BMC Bioinforma. 21, 549 (2020).","journal-title":"BMC Bioinforma."},{"key":"1308_CR34","doi-asserted-by":"publisher","unstructured":"Al Assaad, M. et al. The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer. Cold Spring Harb. Mol. Case Stud. 9 https:\/\/doi.org\/10.1101\/mcs.a006275 (2023).","DOI":"10.1101\/mcs.a006275"},{"key":"1308_CR35","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1158\/1538-7445.AM2023-3437","volume":"83","author":"MA Assaad","year":"2023","unstructured":"Assaad, M. A. et al. Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues. Cancer Res. 83, 3437\u20133437 (2023).","journal-title":"Cancer Res."},{"key":"1308_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/PAS.0000000000002159","volume":"48","author":"E Hissong","year":"2024","unstructured":"Hissong, E. et al. NIPBL: NACC1 fusion hepatic carcinoma. Am. J. Surg. Pathol. 48, 183\u2013193 (2024).","journal-title":"Am. J. Surg. Pathol."},{"key":"1308_CR37","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000002099","volume":"47","author":"NL Mendelson","year":"2023","unstructured":"Mendelson, N. L. et al. Whole-genome analysis elucidates complex genomic events in GLI1 -rearranged enteric tumor. Am. J. Surg. Pathol. 47, 1192\u20131193 (2023).","journal-title":"Am. J. Surg. Pathol."},{"key":"1308_CR38","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013d947 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1308_CR39","doi-asserted-by":"publisher","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 2017 https:\/\/doi.org\/10.1200\/po.17.00011 (2017).","DOI":"10.1200\/po.17.00011"},{"key":"1308_CR40","doi-asserted-by":"publisher","first-page":"100452","DOI":"10.1016\/j.modpat.2024.100452","volume":"37","author":"M Al Assaad","year":"2024","unstructured":"Al Assaad, M. et al. Whole-genome sequencing analysis of male breast cancer unveils novel structural events and potential therapeutic targets. Mod. Pathol. 37, 100452 (2024).","journal-title":"Mod. Pathol."},{"key":"1308_CR41","unstructured":"BACPAC Resources, https:\/\/bacpacresources.org\/ (2000)."},{"key":"1308_CR42","first-page":"221","volume":"5","author":"R Kundra","year":"2021","unstructured":"Kundra, R. et al. OncoTree: a cancer classification system for precision oncology. JCO Clin. Cancer Inf. 5, 221\u2013230 (2021).","journal-title":"JCO Clin. Cancer Inf."},{"key":"1308_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea, A. D. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 71, 172\u2013176 (2018).","journal-title":"DNA Repair"},{"key":"1308_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","volume":"16","author":"Z Feng","year":"2023","unstructured":"Feng, Z. et al. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J. Ovarian Res 16, 53 (2023).","journal-title":"J. Ovarian Res"},{"key":"1308_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley, D. M., Krivak, T. C., Kabil, N., Munley, J. & Moore, K. N. PARP inhibitors in ovarian cancer: a review. Target Oncol. 18, 471\u2013503 (2023).","journal-title":"Target Oncol."},{"key":"1308_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-023-00368-x","volume":"7","author":"ES Tsang","year":"2023","unstructured":"Tsang, E. S. et al. Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration. npj Precis. Oncol. 7, 31 (2023).","journal-title":"npj Precis. Oncol."},{"key":"1308_CR47","doi-asserted-by":"publisher","unstructured":"Fountzilas, E. et al. Concordance between three homologous recombination deficiency (HRD) assays in patients with high-grade epithelial ovarian cancer. Cancers 15 https:\/\/doi.org\/10.3390\/cancers15235525 (2023).","DOI":"10.3390\/cancers15235525"},{"key":"1308_CR48","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1158\/1078-0432.CCR-19-2135","volume":"26","author":"Z Sztupinszki","year":"2020","unstructured":"Sztupinszki, Z. et al. Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1\/2 mutations. Clin. Cancer Res. 26, 2673\u20132680 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1308_CR49","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.modpat.2022.100049","volume":"36","author":"KD Doig","year":"2023","unstructured":"Doig, K. D., Fellowes, A. P. & Fox, S. B. Homologous recombination repair deficiency: an overview for pathologists. Mod. Pathol. 36, 100049 (2023).","journal-title":"Mod. Pathol."},{"key":"1308_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13000-023-01431-8","volume":"19","author":"A Vogel","year":"2024","unstructured":"Vogel, A., Haupts, A., Kloth, M., Roth, W. & Hartmann, N. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations. Diagn. Pathol. 19, 9 (2024).","journal-title":"Diagn. Pathol."},{"key":"1308_CR51","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1038\/s41388-022-02363-1","volume":"41","author":"TG Meijer","year":"2022","unstructured":"Meijer, T. G. et al. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests. Oncogene 41, 3498\u20133506 (2022).","journal-title":"Oncogene"},{"key":"1308_CR52","doi-asserted-by":"crossref","unstructured":"Lee, C., Leem, J. & Oh, J. S. Selective utilization of non\u2010homologous end\u2010joining and homologous recombination for DNA repair during meiotic maturation in mouse oocytes. Cell Prolif. 56, e13384 (2022).","DOI":"10.1111\/cpr.13384"},{"key":"1308_CR53","unstructured":"Treatment by cancer type. NCCN Available at: https:\/\/www.nccn.org\/guidelines\/category_1. (Accessed: 12th December 2025)."},{"key":"1308_CR54","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","volume":"23","author":"S Lheureux","year":"2017","unstructured":"Lheureux, S. et al. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization. Clin. Cancer Res 23, 4086\u20134094 (2017).","journal-title":"Clin. Cancer Res"},{"key":"1308_CR55","doi-asserted-by":"publisher","unstructured":"Stires, H. et al. Abstract A017: An analysis of 13 independently performed assays to measure homologous recombination deficiency using 90 freshly extracted high grade serous ovarian tumors: Findings from the Friends of Cancer Research Hrd Harmonization Project. Cancer Res. 84, https:\/\/doi.org\/10.1158\/1538-7445.OVARIAN23-A017 (2024).","DOI":"10.1158\/1538-7445.OVARIAN23-A017"},{"key":"1308_CR56","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cjp2.271","volume":"8","author":"J Budczies","year":"2022","unstructured":"Budczies, J. et al. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. J. Pathol. Clin. Res. 8, 371\u2013382 (2022).","journal-title":"J. Pathol. Clin. Res."},{"key":"1308_CR57","doi-asserted-by":"publisher","unstructured":"Abbasi, A. et al. Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancers. medRxiv, 2024.2007.2014.24310383 https:\/\/doi.org\/10.1101\/2024.07.14.24310383 (2024).","DOI":"10.1101\/2024.07.14.24310383"},{"key":"1308_CR58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrg.2015.25","volume":"17","author":"CM Carvalho","year":"2016","unstructured":"Carvalho, C. M. & Lupski, J. R. Mechanisms underlying structural variant formation in genomic disorders. Nat. Rev. Genet. 17, 224\u2013238 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"1308_CR59","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1158\/1078-0432.CCR-20-4068","volume":"27","author":"A Ewing","year":"2021","unstructured":"Ewing, A. et al. Structural variants at the BRCA1\/2 loci are a common source of homologous repair deficiency in high-grade serous ovarian carcinoma. Clin. Cancer Res. 27, 3201\u20133214 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1308_CR60","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-20-0255","volume":"26","author":"P Bouwman","year":"2020","unstructured":"Bouwman, P. et al. Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays. Clin. Cancer Res. 26, 4559\u20134568 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1308_CR61","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jjco\/hyz090","volume":"49","author":"K Matsumoto","year":"2019","unstructured":"Matsumoto, K. et al. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Jpn J. Clin. Oncol. 49, 703\u2013707 (2019).","journal-title":"Jpn J. Clin. Oncol."},{"key":"1308_CR62","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","volume":"3","author":"JJ Gruber","year":"2022","unstructured":"Gruber, J. J. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat. Cancer 3, 1181\u20131191 (2022).","journal-title":"Nat. Cancer"},{"key":"1308_CR63","unstructured":"UIMC1 ubiquitin interaction motif containing 1 [homo sapiens (human)] - gene - NCBI. National Center for Biotechnology Information Available at: https:\/\/www.ncbi.nlm.nih.gov\/gene\/51720. (Accessed: 12th December 2025)."},{"key":"1308_CR64","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","volume":"101","author":"JW Chiang","year":"2006","unstructured":"Chiang, J. W., Karlan, B. Y., Cass, L. & Baldwin, R. L. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol. Oncol. 101, 403\u2013410 (2006).","journal-title":"Gynecol. Oncol."},{"key":"1308_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40661-017-0039-8","volume":"4","author":"MK Frey","year":"2017","unstructured":"Frey, M. K. & Pothuri, B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol. Oncol. Res. Pr. 4, 4 (2017).","journal-title":"Gynecol. Oncol. Res. Pr."},{"key":"1308_CR66","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1038\/s41598-023-35092-w","volume":"13","author":"Z Shi","year":"2023","unstructured":"Shi, Z. et al. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types. Sci. Rep. 13, 8899 (2023).","journal-title":"Sci. Rep."},{"key":"1308_CR67","unstructured":"Weill Cornell Cancer Precision Medicine Program - WC-CPMP. ICGC ARGO Available at: https:\/\/www.icgc-argo.org\/page\/90\/wccpmp. (Accessed: 12th December 2025)."},{"key":"1308_CR68","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41391-021-00324-5","volume":"24","author":"AJ Armstrong","year":"2021","unstructured":"Armstrong, A. J. et al. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer Prostatic Dis. 24, 786\u2013793 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1308_CR69","doi-asserted-by":"publisher","unstructured":"Sailer, V. et al. Integrative molecular analysis of patients with advanced and metastatic cancer. JCO Precis. Oncol. 3 https:\/\/doi.org\/10.1200\/po.19.00047 (2019).","DOI":"10.1200\/po.19.00047"},{"key":"1308_CR70","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1001\/jamaoncol.2015.1313","volume":"1","author":"H Beltran","year":"2015","unstructured":"Beltran, H. et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol. 1, 466\u2013474 (2015).","journal-title":"JAMA Oncol."},{"key":"1308_CR71","doi-asserted-by":"publisher","first-page":"1274163","DOI":"10.3389\/fonc.2023.1274163","volume":"13","author":"M Al Assaad","year":"2023","unstructured":"Al Assaad, M. et al. Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis. Front Oncol. 13, 1274163 (2023).","journal-title":"Front Oncol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01308-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01308-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:02:05Z","timestamp":1768212125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01308-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1308"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01308-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4978638\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kevin Hadi, Max F. Levine, Gunes Gundem, Juan S. Medina-Martinez, Minal Patel and Elli Papaemmanuil are Isabl, Inc. employees. All other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}